Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13461523 | 1.00 | LAP3 (0.48) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL2849500 | 0.83 | TP53 (0.39) | LAP3RNPEPSLC7A5FOLH1SLC1A3 | |
| SCHEMBL25564416 | 0.81 | SLC7A5 (0.43) | LAP3RNPEPSLC7A5ALDH1A1SLC1A3 | |
| Hydrochloric Acid SCHEMBL10486450 | 0.81 | LAP3 (0.50) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| Hydrochloric Acid SCHEMBL11385922 | 0.81 | LAP3 (0.50) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL1781745 | 0.80 | LAP3 (0.36) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL14560234 | 0.80 | LAP3 (0.36) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL14445462 | 0.80 | SLC1A3 (0.34) | LAP3RNPEPSLC7A5SLC1A3SLC1A2 | |
| SCHEMBL11789757 | 0.78 | LAP3 (0.52) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL12951606 | 0.78 | MME (0.41) | LAP3FOLH1ALDH1A1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298001-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | CORSAIR PHARMA INC (US) | 2017-10-19 | — | — | US | disclosed |
| EP-2697191-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012139888-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-18 | — | — | WO | disclosed |
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| WO-2007056280-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056184-A2 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-0758013-B1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL CO LTD (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0021766-B1 | INHIBITORS OF MAMMALIAN COLLAGENASE | E.R. Squibb & Sons, Inc. (US) | 1983-02-09 | — | — | EP | disclosed |
| US-4310514-A | VACCINES | MERCK & CO., INC. (US) | 1982-01-12 | — | — | US | disclosed |
| US-4297275-A | Inhibitors of mammalian collagenase | E. R. SQUIBB & SONS, INC. (US) | 1981-10-27 | — | — | US | disclosed |
| EP-0021766-A2 | Inhibitors of mammalian collagenase | E.R. Squibb & Sons, Inc. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4235885-A | Inhibitors of mammalian collagenase | E. R. SQUIBB & SONS, INC. (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298001-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | LAP3 440/4885RNPEP 572/4885SLC7A5 3332/4885 |
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | ALDH1A2, ALDH1A3, GRHPR | LAP3 969/4885RNPEP 1894/4885SLC7A5 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.